Raptor adds new member to board of directors

NOVATO, Calif. Drug maker Raptor Pharmaceutical Corp. announced Thursday the appointment of Light Sciences Oncology CEO and president Llew Keltner to its board of directors.

In his new position at Raptor, Keltner will help with the design and execution of clinical trials of drugs for treating genetic diseases and cancer.

“With over 30 years in the healthcare industry, Dr. Keltner’s expertise in genetic analyses will be extremely valuable as we work to advance our development programs in various indications, including cancers, genetic diseases and liver disorders,” Raptor CEO Christopher Starr said in a statement. “Dr. Keltner has also advised healthcare and financial companies through the challenges of raising capital and obtaining approval of new pharmacologic entities.”

Raptor, which recently listed on the NASDAQ, has several drug candidates in clinical development for treating Huntington’s disease, non-alcoholic steatohepatitis and other conditions.